Revere Drug/Medical Device Reports ::
The Revere Drug/Medical Device Report gives a comprehensive assessment of the performance and risk of both FDA- approved and pipeline products for all U.S. and Canadian listed biotech and pharmaceutical companies (including ADRs).
Each Revere Drug/Medical Device Report includes a detailed presentation of a company’s drugs/devices--both existing and in development-- including their indications, clinical trial status (i.e. pre-clinical, Phase 1, Phase 2, Phase 3, NDA/BLA-filed, IDE-filed, 510K/PMA-filed, Approvable Letter Received), and primary mechanism of action.
In addition, the identifies the diseases/conditions on which the company focuses and its plans to add indications for existing products or expand its product pipeline. Daily monitoring and updating ensures that provide accurate and up-to-date information.
Sample individual reports:
- Drug/Medical Device for Amgen, Inc. (AMGN) Revere - Jan 27, 2007 - PDF - View Report »
Individual Drug/Medical Device Reports are available for purchase in our store, www.reveredata.com/reports/store, and are also bundled with our flagship Revere Research software.